Ultrahuman key facts
- Developer of metabolic health and fitness monitoring devices intended to help users transform themselves.
- Ultrahuman’s last known valuation is $575.0M.
- It has raised $109.9M.
- Notable investors include Blume Venture Advisors, Kunal Shah, Rainmatter Capital, Nexus Venture Partners, Alpha Wave Global — 25 tracked in total.
- Status: Privately Held (backing).
Who backs Ultrahuman
25+- ·The complete investor list: 25 names
- ·Watch Ultrahuman: the Monday email on marks, rounds and moves
Ultrahuman funding rounds
No funding rounds for Ultrahuman are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Ultrahuman valuation
Ultrahuman's last known valuation is $575 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Ultrahuman investors
25 investors are on record for Ultrahuman, including Blume Venture Advisors, Kunal Shah, Rainmatter Capital and Nexus Venture Partners. By type, the record holds 3 venture capital firms, 1 asset manager and 1 growth equity firm.
About Ultrahuman
Developer of metabolic health and fitness monitoring devices intended to help users transform themselves. The company's devices monitor environmental markers that affect users' health every day and allow them to track their meditation, body workouts, and bedtime, enabling users to meditate, work, and optimize their sleep efficiently.
- Sector
- Healthcare
- HQ
- Bangalore, India
- Founded
- 2019
- Employees
- 125
- Website
- ultrahuman.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Ultrahuman’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.